Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Regeneron Pharmaceuticals    REGN


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

FDA Authorizes Regeneron's Covid-19 Antibody Cocktail Drug -- Update

11/21/2020 | 09:27pm EST

By Joseph Walker

Regeneron Pharmaceuticals Inc.'s Covid-19 antibody drug was authorized Saturday by U.S. health regulators, the second cleared this month to treat patients who aren't hospitalized but are at high risk of developing severe disease.

The Food and Drug Administration cleared the antibody drug cocktail for use treating mild to moderate Covid-19 patients 12 years of age and older, including people older than 65 years.

Regeneron's drug combines two lab-made antibodies designed to latch onto the novel coronavirus and prevent it from replicating and hijacking human cells. The treatment is still being tested in clinical trials, after being developed by Regeneron scientists in Tarrytown, N.Y., earlier this year.

In October, it was one of three pharmaceutical treatments given to President Trump for treatment of Covid-19. Mr. Trump later attributed his recovery. "They gave me Regeneron, and it was like, unbelievable. I felt good immediately," he said.

The FDA said it authorized the drug's emergency use, a kind of clearance the agency has been using during the pandemic to speed up access to medicines.

The FDA said its authorization was based on a study of about 800 people. In the study, 3% of subjects taking Regeneron's drug and who were at high risk of severe disease had to be hospitalized or visit emergency rooms, compared with 9% of patients who received a placebo.

"The emergency authorization of these monoclonal antibodies administered together offers health care providers another tool in combating the pandemic," Patrizia Cavazzoni, M.D., acting director of the FDA's Center for Drug Evaluation and Research, said in a statement.

Earlier this month, the FDA issued an emergency authorization for an antibody drug made by Eli Lilly & Co. for a similar set of patients.

The FDA didn't authorize the treatments for hospitalized patients. In the sickest patients, those requiring high-flow oxygen support or mechanical ventilation while hospitalized, monoclonal antibodies such as Regeneron and Eli Lilly's drugs could make patients sicker, the FDA warned.

The Eli Lilly and Regeneron drugs are the first to show promising results in treating patients who haven't yet been hospitalized, filling a big hole in treatment.

Previous drugs cleared for Covid-19 use, such as Gilead Sciences Inc.'s remdesivir, were authorized for hospitalized patients.

Lilly and Regeneron were among the first to set out to develop antibody drugs for Covid-19 after the virus's genetic sequence was published in January. Other companies working on the therapies include AstraZeneca PLC, GlaxoSmithKline PLC and Vir Biotechnology Inc.

Antibodies are soldiers in the body's immune system that help it fight off pathogens. Lab-made antibody drugs mimic their natural counterparts.

Lilly's antibody drug was derived from antibodies isolated from the blood of a patient who recovered from Covid-19. Regeneron's drug combines an antibody from a recovered patient and one generated by mice with genetically modified immune systems.

The drugs are made from living cells, a process that is more complicated and expensive than making pills. Both companies say shortages are likely given the expected demand.

Regeneron has agreed to provide the first 300,000 doses to the U.S. government as part of a $450 million contract signed in July.

Regeneron said it would have enough doses of its drug to treat 80,000 patients by the end of November, an additional 120,000 doses in the first week of January, and another 100,000 doses by the end of January 2021.

The drug cocktail contains antibodies named casirivimab and imdevimab, a combination that formerly went by the code name REGEN-COV2.

"Demand may exceed supply initially, making it even more critical that federal and state governments ensure REGEN-COV2 is distributed fairly and equitably to the patients most in need," Regeneron Chief Executive Leonard Schleifer said in a statement.

An FDA fact sheet on the drug says it may be ineffective against strains of the coronavirus that are resistant to the antibodies.

"We are encouraged that no variants resistant to the cocktail were identified in the clinical trial analyses to date, which is consistent with our preclinical findings," Regeneron Chief Scientific Officer George D. Yancopoulos said in a statement.

Write to Joseph Walker at joseph.walker@wsj.com

(END) Dow Jones Newswires

11-21-20 2126ET

Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -1.00% 7645 Delayed Quote.5.43%
ELI LILLY AND COMPANY 1.40% 201.26 Delayed Quote.17.56%
GILEAD SCIENCES, INC. 1.37% 67.99 Delayed Quote.15.12%
GLAXOSMITHKLINE PLC -2.17% 1379.8 Delayed Quote.5.10%
REGENERON PHARMACEUTICALS 1.57% 542.27 Delayed Quote.10.51%
VIR BIOTECHNOLOGY, INC. 11.32% 43.37 Delayed Quote.45.48%
01/19REGENERON PHARMACEUTICALS : to Report Fourth Quarter and Full Year 2020 Financia..
01/19REGENERON PHARMACEUTICALS : Morgan Stanley Adjusts Regeneron Pharmaceuticals PT ..
01/15REGENERON PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement (fo..
01/13S&P closes higher with defensive sectors leading gains
01/13Wall St gains steadily while impeachment hearings get underway
01/13SECTOR UPDATE : Health Care Stocks Trading Lower Premarket Wednesday
01/13REGENERON PHARMACEUTICALS : Benchmark Upgrades Regeneron Pharmaceuticals to Buy ..
01/13TIZIANA LIFE SCIENCES : Names Chief Medical Officer
01/13TIZIANA LIFE SCIENCES : Science Appoints New Chief Medial Officer; Shares Up 13%
01/12REGENERON PHARMACEUTICALS : to Supply U.S. Government with up to 1.25 Million Do..
More news
Financials (USD)
Sales 2020 8 546 M - -
Net income 2020 3 178 M - -
Net cash 2020 5 478 M - -
P/E ratio 2020 19,3x
Yield 2020 -
Capitalization 57 234 M 57 234 M -
EV / Sales 2020 6,06x
EV / Sales 2021 4,52x
Nbr of Employees 8 314
Free-Float 83,1%
Duration : Period :
Regeneron Pharmaceuticals Technical Analysis Chart | REGN | US75886F1075 | MarketScreener
Technical analysis trends REGENERON PHARMACEUTICALS
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 654,96 $
Last Close Price 542,27 $
Spread / Highest target 46,2%
Spread / Average Target 20,8%
Spread / Lowest Target -7,80%
EPS Revisions
Managers and Directors
Leonard S. Schleifer Co-President, Chief Executive Officer & Director
George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
P. Roy Vagelos Chairman
Patrice Gilooly Senior VP-Quality Assurance & Operations
Robert E. Landry Chief Financial Officer & Executive VP-Finance
Sector and Competitors
1st jan.Capitalization (M$)
WUXI APPTEC CO., LTD.14.44%53 987
BEIGENE, LTD.38.04%32 523
GENMAB A/S10.03%28 876